Validation of Aβ1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease

Brain Research

Volumn 1280, Issue , 2009, Pages 137-147

  Takeda, Shuko ^a   Sato, Naoyuki ^a   Niisato, Kazue ^b   Takeuchi, Daisuke ^a   Kurinami, Hitomi ^a   Shinohara, Mitsuru ^a   Rakugi, Hiromi ^a   Kano, Masanobu ^c   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

amyloid; Alzheimer disease; Animal model

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; GALANTAMINE; AMYLOID BETA PROTEIN; NEUROTOXIN; NOOTROPIC AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN VENTRICLE; COGNITIVE DEFECT; CONSTRUCT VALIDITY; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FACE VALIDITY; HIPPOCAMPUS; INJECTION; LONG TERM POTENTIATION; MALE; MEMORY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; VALIDATION STUDY; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEMORY DISORDER; PHYSIOLOGY;

ANIMALIA; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CEREBRAL VENTRICLES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GALANTAMINE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; MALE; MEMORY; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; NEUROTOXINS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS;

EID: 67649438788     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.05.035     Document Type: Article

References (43)

1. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., and Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282 (2007) 11590-11601
2. Fox N.C., Warrington E.K., Freeborough P.A., Hartikainen P., Kennedy A.M., Stevens J.M., and Rossor M.N. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 Pt. 6 (1996) 2001-2007
3. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
4. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
5. Granholm E., and Butters N. Associative encoding and retrieval in Alzheimer's and Huntington's disease. Brain Cogn. 7 (1988) 335-347
6. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
7. Harkany T., O'Mahony S., Kelly J.P., Soos K., Toro I., Penke B., Luiten P.G., Nyakas C., Gulya K., and Leonard B.E. Beta-amyloid(Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav. Brain Res. 90 (1998) 133-145
8. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., Konya C., Sebens J.B., Korf J., Nyakas C., Zarandi M., Soos K., Penke B., and Luiten P.G. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 12 (2000) 2735-2745
9. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev., Neurosci. 5 (2004) 347-360
10. Jack Jr. C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., and Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (1999) 1397-1403
11. Jarrett J.T., Berger E.P., et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
12. Kobayashi K., Noda Y., Matsushita N., Nishii K., Sawada H., Nagatsu T., Nakahara D., Fukabori R., Yasoshima Y., Yamamoto T., Miura M., Kano M., Mamiya T., Miyamoto Y., and Nabeshima T. Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene. J. Neurosci. 20 (2000) 2418-2426
13. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
14. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
15. Lynch M.A. Long-term potentiation and memory. Physiol. Rev. 84 (2004) 87-136
16. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., and Takeshima H. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394 (1998) 577-581
17. Martin A., Brouwers P., Cox C., and Fedio P. On the nature of the verbal memory deficit in Alzheimer's disease. Brain Lang. 25 (1985) 323-341
18. Nag S., Yee B.K., and Tang F. Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40). Brain Res. Bull. 50 (1999) 251-262
19. Nakamura S., Murayama N., Noshita T., Annoura H., and Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain Res. 912 (2001) 128-136
20. Nitta A., Itoh A., Hasegawa T., and Nabeshima T. beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170 (1994) 63-66
21. Niwa K., Younkin L., et al. Abeta1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9735-9740
22. Olariu A., Yamada K., Mamiya T., Hefco V., and Nabeshima T. Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C. Brain Res. 957 (2002) 278-286
23. Raskind M.A., Peskind E.R., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54 (2000) 2261-2268
24. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
25. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., and Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866-2875
26. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
27. Staubli U., Thibault O., DiLorenzo M., and Lynch G. Antagonism of NMDA receptors impairs acquisition but not retention of olfactory memory. Behav. Neurosci. 103 (1989) 54-60
28. Steele R.J., and Morris R.G. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 9 (1999) 118-136
29. Sweeney J.E., Bachman E.S., and Coyle J.T. Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology (Berl) 102 (1990) 191-200
30. Tajima H., Kawasumi M., Chiba T., Yamada M., Yamashita K., Nawa M., Kita Y., Kouyama K., Aiso S., Matsuoka M., Niikura T., and Nishimoto I. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res. 79 (2005) 714-723
31. Takeuchi D., Sato N., et al. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 15 (2008) 561-571
32. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., and Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54 (2000) 2269-2276
33. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
34. Van Dam D., and De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat. Rev., Drug Discov. 5 (2006) 956-970
35. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., and De Deyn P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17 (2003) 388-396
36. Van Dam D., Abramowski D., Staufenbiel M., and De Deyn P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180 (2005) 177-190
37. Weingartner H., Grafman J., Boutelle W., Kaye W., and Martin P.R. Forms of memory failure. Science 221 (1983) 380-382
38. Weller R.O., Massey A., et al. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153 (1998) 725-733
39. Wilcock G.K., Lilienfeld S., and Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321 (2000) 1445-1449
40. Yamada K., and Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 88 (2000) 93-113
41. Yamada K., Tanaka T., Zou L.B., Senzaki K., Yano K., Osada T., Ana O., Ren X., Kameyama T., and Nabeshima T. Long-term deprivation of oestrogens by ovariectomy potentiates beta-amyloid-induced working memory deficits in rats. Br. J. Pharmacol. 128 (1999) 419-427
42. Yamada M., Chiba T., Sasabe J., Nawa M., Tajima H., Niikura T., Terashita K., Aiso S., Kita Y., Matsuoka M., and Nishimoto I. Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav. Brain Res. 164 (2005) 139-146
43. Yamaguchi Y., Miyashita H., Tsunekawa H., Mouri A., Kim H.C., Saito K., Matsuno T., Kawashima S., and Nabeshima T. Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat. J. Pharmacol. Exp. Ther. 317 (2006) 1079-1087